4/2/2025, 2:15:00 PM | Seeking Alpha | news
TG Therapeutics stock rises as Roche’s trial fails (TGTX)
Roche's Phase 3 trial for a high-dose version of its multiple sclerosis therapy Ocrevus failed, leading to a rise in the stock prices of TG Therapeutics, a rival MS drug developer.